ArticleJournal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada2025
Appropriateness of intravenous vancomycin prescribing in a Canadian acute care hospital.
Article in Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: There are associated adverse effects with intravenous (IV) vancomycin, yet there is a paucity of published literature surveying the appropriateness of use. The objective of the study was to assess the appropriateness of IV vancomycin prescriptions at a Canadian acute care hospital. Methods: A pilot, pragmatic antimicrobial stewardship initiative using prospective audit and feedback (PAF) was conducted on incident IV vancomycin prescriptions for 4 weeks in 2022. The primary outcome was the percentage of IV vancomycin prescriptions assessed as appropriate against institutional prescribing guidelines. The secondary outcomes were to evaluate factors affecting appropriateness and to determine the number and types of ASP recommendations where IV vancomycin was assessed as suboptimal. Results: Out of 109 prescriptions audited, 43 (39%) were assessed to be suboptimal. Discontinuing or changing the agent was recommended in 39 cases (91%) and regimen optimization (duration or frequency change) was only recommended in only 4 (9%). ASP recommendations were fully or partially accepted in 88%. Infectious disease consultation (IDC) was associated with greater appropriateness (83% versus 53%; Conclusions: Prospective audit and feedback demonstrated inappropriate IV vancomycin use at our centre and an opportunity for quality improvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.